Search clinical trials for: Mirabegron 25mg

Total 1826 results

Nivalis Therapeutics, Inc.

Completed

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

Healthy

United States
Beijing Union Pharmaceutical Factory Ltd
R&G Pharma Studies Co.,Ltd.

Recruiting

Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD (BGFN-2022-01)

Generalized Anxiety Disorder

China
Xentria, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

Healthy Participants

United States
Yooyoung Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)

GERD

Korea, Republic of
Zeria Pharmaceutical

Completed

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Healthy

Japan
Vista Klinik
Bayer

Completed

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

Neovascular Age-related Macular Degeneration
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc.; Sisters of the Third Order of...

Terminated

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Pain | Urinary Bladder, Overactive | Lower Urinary Tract Symptoms

United States
The University of Texas Health Science Center at...

Completed

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron (SCIMYR)

Cognitive Change | Spinal Cord Injuries | Neurogenic Bladder

United States
Loyola University
Astellas Pharma US, Inc.

Completed

Mirabegron and Urinary Urgency Incontinence

Overactive Bladder

United States
Astellas Pharma Inc

Completed

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

Urinary Bladder, Overactive

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Overactive Bladder | Cardiovascular Disease

Japan
Astellas Pharma Inc

Completed

Drug Use-Results Survey of Betanis Tablets in Japan

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

Intraocular Pressure

United States
University of Maryland, Baltimore
Nico Corporation

Recruiting

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone (ENRICHPLUS)

Intracerebral Haemorrhage, Intraventricular

United States
Memorial Blood Centers, Minnesota

Completed

Iron Depletion and Replacement in Blood Donors

Anemia

United States
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Daewoong Pharmaceutical Co. LTD.

Completed

Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers

Healthy

Korea, Republic of
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

Arterial Hypertension
Daewoong Pharmaceutical Co. LTD.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

Peptic Ulcer

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID) (CAPTOCOVID)

COVID-19 | Coronavirus Infection | Pneumonia

France
Samyang Biopharmaceuticals Corporation
Chungnam National University Hospital

Completed

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Healthy, Male
Yuhan Corporation

Completed

Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers

Hypertension

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Enrolling by invitation

Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects (DWJ1610)

Drug-drug Interaction

Korea, Republic of
Astellas Pharma Global Development, Inc.

Terminated

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

Pharmacokinetics of Mirabegron | Overactive Bladder (OAB)

Korea, Republic of, Russian Federation, Turkey
Servier

Completed

Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

Essential Hypertension

Russian Federation
Theodore R. Brown, MD MPH
Astellas Pharma Inc

Completed

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States
Baylor College of Medicine

Completed

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction | Flank Pain

United States
University Hospital, Lille

Active, not recruiting

Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03)

Multiple Myeloma

France
Daniel Burdick, MD
Astellas Pharma US, Inc.

Completed

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) (Maestro)

Parkinsons Disease

United States
Henning Bundgaard

Completed

Beta 3 Agonist Treatment in Heart Failure (Beat-HF)

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Australia, Denmark
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Herpes Zoster

Australia
Dartmouth-Hitchcock Medical Center

Completed

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

Anemia, Iron-Deficiency | Cystic Fibrosis

United States
Pfizer

Completed

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

Canada, United States, France, Denmark, Finland, Germany
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
Hanlim Pharm. Co., Ltd.

Completed

Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia
Addpharma Inc.

Completed

A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole

Gastritis

Korea, Republic of
Paddock Laboratories, Inc.

Completed

A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

Healthy

United States
Huahui Health

Terminated

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Chronic Hepatitis B and Hepatitis D Co-infection

China
Hull University Teaching Hospitals NHS Trust

Completed

Azithromycin a Treatment for Pulmonary Sarcoidosis (CAPS)

Sarcoidosis, Pulmonary

United Kingdom
AGI Therapeutics, Inc.

Completed

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) (ARDIS-1)

Irritable Bowel Syndrome With Diarrhea

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Schizophrenia

Japan
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Rheumatoid Arthritis

Korea, Republic of
Handok Inc.

Completed

Teneligliptin and Atorvastatin DDI Study

Diabete Mellitus

Korea, Republic of

3

Subscribe